NCT01837420 is a Phase 2 clinical trial of VB-201 80mg in Psoriasis, sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics.

Who is sponsoring NCT01837420?

NCT01837420 is sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics.

What drugs are being tested in NCT01837420?

Interventions in NCT01837420: VB-201 80mg, VB-201 160mg, Placebo.

Is NCT01837420 still recruiting?

NCT01837420 is currently completed. Last updated 26 March 2015.

Last reviewed 2015-03-26 · How we verify

NCT01837420

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Double Blind, Dose Ranging, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis

Completed Phase 2 Last updated 26 March 2015

What this trial tests

Phase 2 trial testing VB-201 80mg in Psoriasis in 194 participants. Completed in 1 November 2014.

Timeline

1 November 2012

Primary endpoint
1 November 2014

1 November 2014

Quick facts

Lead sponsor	Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	194
Start date	1 November 2012
Primary completion	1 November 2014
Estimated completion	1 November 2014
Sites	4 locations across Germany, Israel, Poland, Spain

Drugs / interventions tested

VB-201 80mg — full drug profile →
VB-201 160mg — full drug profile →
Placebo

Conditions studied

Psoriasis — all drugs for Psoriasis →

Sponsor

Vascular Biogenics Ltd. operating as VBL Therapeutics — full company profile →

Who can join

Adults 18 to 75, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

PASI 50
Time frame: Week 16 and Week 24
The proportion of subjects in the VB-201 160 mg (80 mg BID) treatment group who achieve at least 50% improvement from the baseline PASI score at Weeks 16 and 24 (PASI 50) compared to the proportion of PASI 50 responders in the placebo group.

Sponsor's own description

This study will examine the safety and efficacy in subjects with moderate to severe psoriasis, as measured by Psoriasis Area and Severity Index(PASI), Body Surface Area (BSA), Dermatology Life Quality Index (DLQI) and other assessments.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Small Molecule NF-κB Pathway Inhibitors in Clinic.
Ramadass V, Vaiyapuri T, Tergaonkar V. · · 2020 · cited 154× · PMID 32708302 · DOI 10.3390/ijms21145164

Verify or expand the search:

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting

Other Vascular Biogenics Ltd. operating as VBL Therapeutics trials

Trials by the same sponsor.

NCT04733833 — A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19 · Phase 2 · completed
NCT03398655 — A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01837420 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vascular Biogenics Ltd. operating as VBL Therapeutics
Last refreshed: 26 March 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01837420.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing